CD4 and myeloid sarcoma: showed that natalizumab-treatment results in a CD161+ CD4+ T cell population with several similar characteristics being retained in the circulation, and that low-frequent hits of cells with a similar transcriptome could be revealed with spatial RNA sequencing among local T cell infiltrates in chronic MS.23